Serina Therapeutics to present POZ-lipid data at mRNA Summit; no anti-PEG antibody response

Serina Therapeutics, Inc.

Randall Moreadith, MD, PhD, CDO, will present at 4th Annual mRNA-Based Therapeutics Summit in Boston, July 29-31, 2024.
POZ-lipid does not induce IgM or IgG antibody response in repeated in vivo dosing, unlike current PEG-lipids in mRNA vaccines.
This technology may reduce risk of serious adverse events like anaphylaxis linked to anti-PEG antibodies.
Presentation scheduled for 9:00 AM ET on Monday, July 29, 2024.
Serina's POZ Platform is being developed for neurological diseases, cancer, and other indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.